NAUT revenueQ3 2026$234.0K
- QoQ
- +23.2%
NAUT revenue was $234.0K in fiscal Q3 2026 (ended Sep 30, 2026), compared with $0 a year earlier and up 23.2% from the prior quarter.
Nautilus Biotechnology Inc. (NAUT) financials
For the twelve months ended Sep 30, 2026, Nautilus Biotechnology Inc. reported -$58.58M of net income.
- Net income, TTM
- -$58.58M
- Free cash flow, TTM
- -$55.13M
- EPS, diluted, TTM
- -$0.46
- Cash
- $10.47M
- Market cap
- $303.1M
FY2020FY2025
FY2020FY2025
NAUT revenue and earnings growth
NAUT net incomeQ3 2026-$15.64M
NAUT net income was -$15.64M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$13.57M a year earlier. For the full fiscal 2025 it was -$59.00M, compared with -$70.78M in fiscal 2024.
NAUT EPSQ3 2026-$0.12
NAUT diluted EPS was -$0.12 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.11 a year earlier. For the full fiscal 2025 it was -$0.47, compared with -$0.56 in fiscal 2024.
NAUT free cash flowQ3 2026-$14.73M
NAUT free cash flow was -$14.73M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$11.45M a year earlier. For the full fiscal 2025 it was -$51.97M, compared with -$61.27M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Research and development | $41.11M | $50.48M | $47.25M | $37.67M | $29.35M | $12.43M |
| Selling, general and admin | $25.73M | $31.00M | $28.90M | $25.95M | $21.15M | $3.31M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$59.00M | -$70.78M | -$63.67M | -$57.92M | -$50.31M | -$15.62M |
| EPS, basic | -$0.47 | -$0.56 | -$0.51 | -$0.46 | -$0.60 | -$0.54 |
| EPS, diluted | -$0.47 | -$0.56 | -$0.51 | -$0.46 | -$0.60 | -$0.54 |
| Diluted shares | 126.3M | 125.4M | 124.9M | 124.6M | 84.5M | 29.1M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $12.39M | $28.65M | $20.40M | $115.48M | $186.46M | $37.22M |
| Current assets | $105.96M | $132.83M | $176.84M | $187.21M | $349.22M | $77.66M |
| Total assets | $191.11M | $242.74M | $305.56M | $350.05M | $398.45M | $85.01M |
| Current liabilities | $7.95M | $7.63M | $9.12M | $6.79M | $5.81M | $3.02M |
| Total liabilities | $34.14M | $34.01M | $40.21M | $35.13M | $34.87M | $6.31M |
| Shareholders' equity | $156.97M | $208.73M | $265.35M | $314.92M | $363.58M | -$29.72M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$50.70M | -$59.15M | -$51.71M | -$45.81M | -$39.24M | -$14.00M |
| Capital expenditures | $1.28M | $2.12M | $2.44M | $2.32M | $2.27M | $921.0K |
| Free cash flow | -$51.97M | -$61.27M | -$54.15M | -$48.13M | -$41.51M | -$14.92M |
| Investing cash flow | $35.22M | $66.25M | -$43.73M | -$25.74M | -$138.96M | -$25.28M |
| Financing cash flow | $214.0K | $1.14M | $368.0K | $562.0K | $327.45M | $75.90M |
| Stock-based compensation | $6.84M | $12.70M | $12.14M | $10.38M | $7.93M | $369.0K |
Key ratios
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $234.0K | $190.0K | $0 | - | $0 | $0 | $0 | - | - | - | - | - |
| Cost of revenue | $24.0K | $15.0K | $0 | - | $0 | $0 | $0 | - | - | - | - | - |
| Gross profit | $210.0K | $175.0K | $0 | - | $0 | $0 | $0 | - | - | - | - | - |
| Research and development | $10.18M | $9.61M | $9.71M | $9.57M | $9.61M | $10.39M | $11.54M | $12.82M | $12.29M | $12.44M | $12.93M | $12.47M |
| Selling, general and admin | $6.77M | $6.33M | $6.42M | $5.85M | $5.87M | $6.70M | $7.31M | $7.16M | $6.81M | $8.35M | $8.68M | $7.54M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$15.64M | -$14.47M | -$14.70M | -$13.78M | -$13.57M | -$15.03M | -$16.61M | -$17.59M | -$16.45M | -$18.01M | -$18.73M | -$17.02M |
| EPS, basic | -$0.12 | -$0.11 | -$0.12 | -$0.11 | -$0.11 | -$0.12 | -$0.13 | -$0.14 | -$0.13 | -$0.14 | -$0.15 | -$0.13 |
| EPS, diluted | -$0.12 | -$0.11 | -$0.12 | -$0.11 | -$0.11 | -$0.12 | -$0.13 | -$0.14 | -$0.13 | -$0.14 | -$0.15 | -$0.13 |
| Diluted shares | 127.2M | 127.1M | 126.6M | - | 126.3M | 126.2M | 126.1M | - | 125.5M | 125.3M | 125.1M | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $10.47M | $13.17M | $14.63M | $12.39M | $24.88M | $35.46M | $34.24M | $28.65M | $5.41M | $25.89M | $26.73M | $20.40M |
| Inventory | $900.0K | $600.0K | $300.0K | - | - | - | - | - | - | - | - | - |
| Current assets | $90.24M | $87.63M | $98.83M | $105.96M | $134.32M | $150.72M | $141.60M | $132.83M | $144.21M | $170.93M | $185.09M | $176.84M |
| Total assets | $148.92M | $163.58M | $177.78M | $191.11M | $200.91M | $213.19M | $227.69M | $242.74M | $259.70M | $272.75M | $288.65M | $305.56M |
| Current liabilities | $9.76M | $8.64M | $8.34M | $7.95M | $8.98M | $8.14M | $8.16M | $7.63M | $8.66M | $8.68M | $9.21M | $9.12M |
| Total liabilities | $32.37M | $32.46M | $33.36M | $34.14M | $31.78M | $32.09M | $33.26M | $34.01M | $36.27M | $37.47M | $39.16M | $40.21M |
| Shareholders' equity | $116.56M | $131.11M | $144.41M | $156.97M | $169.14M | $181.09M | $194.44M | $208.73M | $223.43M | $235.28M | $249.49M | $265.35M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$13.28M | -$13.73M | -$13.10M | -$12.38M | -$11.03M | -$13.35M | -$13.94M | -$14.31M | -$13.11M | -$15.46M | -$16.27M | -$13.90M |
| Capital expenditures | $1.45M | $454.0K | $510.0K | $244.0K | $418.0K | $396.0K | $219.0K | $254.0K | $709.0K | $512.0K | $647.0K | $413.0K |
| Free cash flow | -$14.73M | -$14.18M | -$13.61M | -$12.62M | -$11.45M | -$13.75M | -$14.16M | -$14.56M | -$13.82M | -$15.97M | -$16.91M | -$14.31M |
| Investing cash flow | $10.44M | $12.02M | $14.23M | $787.0K | $452.0K | $14.47M | $19.51M | $37.11M | -$7.50M | $14.29M | $22.35M | -$41.06M |
| Financing cash flow | $26.0K | $244.0K | $1.10M | $101.0K | $0 | $95.0K | $18.0K | $440.0K | $140.0K | $319.0K | $245.0K | $253.0K |
| Stock-based compensation | $1.29M | $1.16M | $1.36M | $1.47M | $1.50M | $1.71M | $2.17M | $3.12M | $3.18M | $3.28M | $3.11M | $3.07M |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 89.7% | 92.1% | - | - | - | - | - | - | - | - | - | - |
| Net margin | -6682.1% | -7615.3% | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | -6293.2% | -7463.2% | - | - | - | - | - | - | - | - | - | - |
| Current ratio | 9.25 | 10.14 | 11.85 | 13.33 | 14.95 | 18.52 | 17.36 | 17.40 | 16.65 | 19.69 | 20.09 | 19.39 |
Source: XBRL data Nautilus Biotechnology Inc. files with the SEC, latest filing dated Oct 27, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
NAUT peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| NAUT | - | - | -$58.58M | - | $303.1M |
| A | $7.37B | +8.6% | $1.44B | 19.5% | $50.80B |
| WAT | $4.64B | +52.5% | $166.14M | 3.6% | $46.83B |
| MTD | $4.20B | +6.5% | $934.07M | 22.2% | $35.31B |
| RVTY | $2.91B | +4.1% | $237.55M | 8.2% | $17.93B |
| AVTR | $6.64B | +0.9% | $337.20M | 5.1% | $10.78B |
| BIO | $2.59B | +1.4% | $1.02B | 39.5% | $10.44B |
| BRKR | $3.51B | +2.2% | -$123.40M | -3.5% | $10.16B |
| TXG | $618.58M | -3.6% | -$67.08M | -10.8% | $8.48B |
NAUT FAQ
6 questionsIs NAUT profitable?
No. Nautilus Biotechnology Inc. reported a net loss of $58.58M for the twelve months ended Sep 30, 2026.How much cash and debt does NAUT have?
Nautilus Biotechnology Inc. reported $10.47M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is NAUT free cash flow?
Nautilus Biotechnology Inc. generated -$55.13M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$52.48M less capital expenditures.What is NAUT earnings per share?
Diluted earnings per share were -$0.46 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.When did NAUT last report financial results?
The latest statements here come from Nautilus Biotechnology Inc.'s 10-Q filed on Oct 27, 2026, covering the period ended Sep 30, 2026.Where does this NAUT financial data come from?
Quantisnow builds these statements from the structured XBRL data Nautilus Biotechnology Inc. files with the SEC. It is provided for information only and is not investment advice.